Monroe, NJ, United States of America

Burcu Selin Aytar

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Burcu Selin Aytar. Retrieved from https://idiyas.com/inventor/burcu-selin-aytar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 25.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Burcu Selin Aytar: Innovator in Pharmaceutical Chemistry

Introduction

Burcu Selin Aytar is a notable inventor based in Monroe, NJ, specializing in pharmaceutical chemistry. With a focus on innovative processes, Aytar has made significant contributions to the field through her research and development efforts.

Latest Patents

Aytar holds a patent for a process related to the preparation of N-((1R,2S,5R)-5-(-butylamino)-2-((S)-3-(7--butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide. This invention generally relates to an improved method for synthesizing this compound, which has potential applications in medicinal chemistry.

Career Highlights

Aytar is currently employed at Bristol-Myers Squibb Company, where she continues to advance her research in drug development. Her work is characterized by a commitment to enhancing pharmaceutical processes and improving drug efficacy.

Collaborations

Aytar collaborates with talented colleagues, including Alina Borovika and Collin Chan, contributing to a dynamic research environment that fosters innovation and creativity.

Conclusion

Burcu Selin Aytar exemplifies the spirit of innovation in the pharmaceutical industry. Her contributions through patents and collaborative efforts highlight her role as a key figure in advancing drug development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…